Results 81 to 90 of about 28,270 (206)

Frequency of dyspnea related to intake of ticagrelor or clopidogrel in patients with chronic coronary syndrome undergoing coronary intervention

Кардиоваскулярная терапия и профилактика
In patients with chronic coronary syndrome, ticagrelor decreases cardiovascular events more efficiently than clopidogrel. In several studies investigating novel P2Y12 inhibitors dyspnea has been detected.
Dunya Habeeb Shnain, Ghassan Mohammed Mahmood, Sara Omar Ahmed   +2 more
doaj   +1 more source

Lifetime cardiovascular management of patients with previous Kawasaki disease. [PDF]

, 2020
Kawasaki disease (KD) is an inflammatory disorder of young children, associated with vasculitis of the coronary arteries with subsequent aneurysm formation in up to one-third of untreated patients.
Brogan, Paul, Burns, Jane C, Cornish, Jacqueline, Diwakar, Vinod, Eleftheriou, Despina, Gordon, John B, Gray, Huon Hamilton, Johnson, Thomas William, Kawasaki Disease Writing Group, on behalf of the Royal College of Paediatrics and Child Health, and the British Cardiovascular Society, Levin, Michael, MacCarthy, Philip, Malik, Iqbal, McCormack, Rachael, Miller, Owen, Tulloh, Robert MR   +14 more
core   +1 more source

Primary cardiovascular preventive effect of thiazolidinedione in adults with type 2 diabetes: A nationwide cohort study in Korea

Journal of Diabetes Investigation, EarlyView.
Among Korean adults with type 2 diabetes and no prior cardiovascular disease, thiazolidinedione use was associated with a lower risk of the primary composite outcome of stroke, myocardial infarction, hospitalization for heart failure, and all‐cause mortality compared to dipeptidyl peptidase‐4 inhibitor use. ABSTRACT Background Thiazolidinediones (TZDs)
Yun Young Choi, Jimin Jeon, Minyoul Baik, Joonsang Yoo, Jinkwon Kim   +4 more
wiley   +1 more source

Critical appraisal of ticagrelor in the management of acute coronary syndrome

Therapeutics and Clinical Risk Management, 2011
James J Nawarskas, Stanley S SnowdenUniversity of New Mexico College of Pharmacy, Albuquerque, NM, USAAbstract: Ticagrelor is a novel P2Y12 receptor antagonist which, like clopidogrel and prasugrel, functions by blocking adenosine diphosphate-mediated ...
Nawarskas JJ, Snowden SS
doaj  

Comparison of P2Y12 inhibitors for mortality and stent thrombosis in patients with acute coronary syndromes: Single center study of 10 793 consecutive ‘real-world’ patients

Platelets, 2017
Three oral platelet P2Y12 inhibitors, clopidogrel, prasugrel, and ticagrelor, are available for reducing the risk of cardiovascular death and stent thrombosis in patients with acute coronary syndromes (ACS).
Rebecca Gosling, Momina Yazdani, Yasir Parviz, Ian R Hall, Ever D. Grech, Julian P Gunn, Robert F. Storey, Javaid Iqbal   +7 more
doaj   +1 more source

Antiplatelet therapy in the primary prevention of cardiovascular disease in patients with chronic obstructive pulmonary disease: protocol of a randomised controlled proof-of-concept trial (APPLE COPD-ICON 2) [PDF]

, 2018
Introduction: The antiplatelet therapy in the primary prevention of cardiovascular disease in patients with chronic obstructive pulmonary disease (APPLE COPD-ICON2) trial is a prospective 2×2 factorial, double-blinded proof-of-concept randomised ...
Ali, H, APPLE COPD-ICON2 Trial Investigators, Burns, G, Chan, D, De Soyza, A, Fisher, A, Holstein, E-M, Howe, N, Kunadian, V, McColl, E, Stocken, D, Thornton, J, Von Wilamowitz-Moellendorff, A, Wilkinson, N   +13 more
core   +1 more source

Early Mobilization After Pacemaker Implantation

Pacing and Clinical Electrophysiology, EarlyView.
ABSTRACT Background The increasing use of cardiac implantable electronic devices (CIED) is leading to a rise in procedure‐related complications. Objective This trial aimed to assess the safety and feasibility of early mobilization and the possibility of same‐day discharge following permanent pacemaker implantation.
Jiří Šmíd, Vlastimil Vančura, Martin Brada, Richard Rokyta   +3 more
wiley   +1 more source

ESVM Guideline on peripheral arterial disease [PDF]

, 2019
International ...
, , , Belch, Jill, Boc, Vinko, Brodmann, Marianne, Bulvas, Miroslav, Canning, Caitriona, Carpentier, Patrick H., Chraim, Ali, Colgan, Mary-Paula, Dimakakos, Evangelos, Dorigo, Walter, Frank, Ulrich, Gottsäter, Anders, Heiss, Christian, Houston, Graeme, Kahan, Thomas, Lawall, Holger, Lindstedt, Isak, Madaric, Juraj, Mahe, Guillaume, Martini, Romeo, Mazzolai, Lucia, Nikol, Sigrid, Olinic, Dan Mircea, Pernod, Giles, Poredoš, Pavel, Przywara, Stanislaw, Pécsvárady, Zsolt, Quéré, Isabelle, Righini, Marc, Roztocil, Karel, Schlager, Oliver, Stanek, Agata, Terlecki, Piotr, Vasic, Dragan, Visonà, Adriana, Wautrecht, Jean-Claude   +38 more
core   +5 more sources

Comparative Long-Term Effect of Three Anti-P2Y12 Drugs after Percutaneous Angioplasty: An Observational Study Based on Electronic Drug Adherence Monitoring [PDF]

, 2017
Aims: Dual platelet inhibition using anti-P2Y12 drugs and aspirin is the standard of care in patients after percutaneous coronary interventions (PCI). Prasugrel and ticagrelor have been shown to be more potent than clopidogrel with less high on-treatment
Bernard Vrijens, Chin B. Eap, Chin B. Eap, Eric Eeckhout, Eric Tousset, Grégoire Wuerzner, Isabelle Bassi, Isabelle Menetrey, Michel Burnier, Olivier Muller, Pierre Fontana, Pierre Fontana, Valentina Forni Ogna   +12 more
core   +3 more sources

Tumor‐educated platelets in cancer diagnostics and prognostics: A critical appraisal and roadmap for clinical translation

International Journal of Cancer, Volume 159, Issue 2, Page 302-319, 15 July 2026.
Abstract Tumor‐educated platelets (TEPs) are emerging as a compelling frontier in liquid biopsy, functioning as dynamic, systemic sensors that sequester and process tumor‐derived biomolecules. This interaction imprints an integrated molecular signature of malignancy—spanning the transcriptome, proteome, lipidome, and crucially, the captured genome ...
Whi‐An Kwon, Min‐Kyung Lee, Eunyong Ahn, Heeyeon Kim, Yong Sang Song, Taejin Ahn   +5 more
wiley   +1 more source